The Nasdaq Biotechnology index was sinking 2.5%.
In company news, Ziopharm (ZIOP) declined nearly 11% after disclosing plans to eliminate 60 positions, representing roughly half of its current workforce, which it said will keep the immuno-oncology company in business through the first half of 2023.
Ensysce Biosciences (ENSC) also dropped almost 11% after the specialty drugmaker late Monday said it had secured $15 million in new funding through a private placement of 5% senior convertible notes with an initial conversion rate of $5.87 per share. Investors also received 5-year warrants to buy up to 1.08 million Ensysce common shares exercisable at $7.63 per share.
To the upside, Sonoma Pharmaceuticals (SNOA) raced nearly 30% higher after beginning over-the-counter sales in the US of its Regenacyn Advanced Scar Gel and Ocucyn Eyelid & Eyelash Cleanser and its MucoClyns decontamination solution in Europe through Amazon.com (AMZN).
|-- Earnings Flash (AQS) AEQUUS PHARMACEUTICALS Repor...|
|Insider Buy: Bitnile Holdings|
|Insider Buy: Macerich|
|Insider Sell: Velodyne Lidar|
|Insider Sell: Xometry|